Dr. Maurizio Chiriva Internati is a renowned immunologist, cancer researcher, and biotech innovator known for his pioneering work in oncology and leadership in translational medicine. As the founder and Dr. Chiriva Internati spearheaded the development of AI-driven immunotherapies and led the company to a successful NASDAQ IPO. He holds multiple doctorates in Immunology and Morphological Sciences nd has served as a professor at leading institutions like MD Anderson Cancer Center. Driven by a passion to bring laboratory breakthroughs to patients, he has identified novel cancer-testis antigens and developed innovative therapeutic platforms. His unique blend of scientific expertise, entrepreneurial vision, and commitment to patient-focused innovation defines his impact in the biotech field.